| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/23/2006 | US20060040267 Transcriptional activator |
| 02/23/2006 | US20060040265 Regulation of novel human asparagine-hydroxylases |
| 02/23/2006 | US20060039998 Remedies |
| 02/23/2006 | US20060039979 Drug delivery system using subconjunctival depot |
| 02/23/2006 | US20060039970 Tamper-resistant oral opioid agonist formulations |
| 02/23/2006 | US20060039937 Composition having antioxidant properties |
| 02/23/2006 | US20060039920 Immunization, scrub typhus of tsutsugamushi disease, HIV |
| 02/23/2006 | US20060039918 Stress proteins and peptides and methods of use thereof |
| 02/23/2006 | US20060039903 Immunomodulation and effect on cell processes relating to serotonin family receptors |
| 02/23/2006 | US20060039883 Biologically active compounds for the modification of bodily odours |
| 02/23/2006 | US20060039868 For use in therapy of chronic obstructive pulmonary disease and asthma; an inhalette capsule contains a mixture of coarser and fine excipient particles |
| 02/23/2006 | CA2575367A1 3-halo-2-oxopropionate salts and esters as novel anticancer agents |
| 02/23/2006 | CA2573974A1 Tgf-.beta. gene expression inhibitor |
| 02/23/2006 | CA2573764A1 Hydantoin derivatives for the treatment of inflammatory disorders |
| 02/22/2006 | EP1627885A1 Polypeptide capable of assisting digestive organ absorption |
| 02/22/2006 | EP1627880A1 Boronic ester and acid compounds, synthesis and uses |
| 02/22/2006 | EP1627875A1 Method for producing cyclic diamine derivative or salt thereof |
| 02/22/2006 | EP1627873A1 Benzofuran compound and medicinal composition containing the same |
| 02/22/2006 | EP1627871A1 Cyclic aminophenyl sulfamate derivative |
| 02/22/2006 | EP1627870A1 Cyanofluoropyrrolidine derivative |
| 02/22/2006 | EP1627869A1 Amide derivative |
| 02/22/2006 | EP1627640A1 Sulfate group transferase inhibitor |
| 02/22/2006 | EP1627639A2 Use of COX-2 inhibitors for the treatment of affective disorders |
| 02/22/2006 | EP1490029A4 Controlled release drug delivery system of pravastatin |
| 02/22/2006 | EP1451368A4 Single nucleotide polymorphisms in gh-1 |
| 02/22/2006 | EP1441735B1 N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase |
| 02/22/2006 | EP1414812B1 Hydroxamic acid derivatives |
| 02/22/2006 | EP1385839B1 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists |
| 02/22/2006 | EP1244805B1 Viral core protein-cationic lipid-nucleic acid-delivery complexes |
| 02/22/2006 | EP1233957B1 Novel amidine derivatives, preparation and use thereof as medicines |
| 02/22/2006 | EP1225881B1 The use of dapoxetine, a rapid-onset selective serotonin reuptake inhibitor, for treating sexual dysfunction |
| 02/22/2006 | EP1224187B1 Certain alkylene diamine-substituted heterocycles |
| 02/22/2006 | EP1208086B1 Benzamide formulation with histone deacetylase inhibitor activity |
| 02/22/2006 | EP1194584B1 Method for producing oligopolysaccharides |
| 02/22/2006 | EP1121431B1 Non-endogenous, constitutively activated human g protein-coupled receptors |
| 02/22/2006 | EP1121156B1 Polymer conjugates of interferon beta- 1a and their uses |
| 02/22/2006 | EP0957929B1 Vascular endothelial growth factor (vegf) nucleic acid ligand complexes |
| 02/22/2006 | EP0814837B2 Use of g class immunoglobulins for the topical treatment of atopic dermatitis |
| 02/22/2006 | CN1739030A Diagnosis and prevention of cancer cell invasion |
| 02/22/2006 | CN1738888A Antioxidant, skin preparation for external use, cosmetic and food |
| 02/22/2006 | CN1738829A New 2',5'-oligoadenylic acid analog |
| 02/22/2006 | CN1738806A Oxo-azabicyclic compounds |
| 02/22/2006 | CN1738636A Use of enzyme inhibitors with aminopeptidase N and/or dipeptidylpeptidase IV activities and pharmaceutical preparations produced therefrom for the therapy and prevention of dermatological diseases wit |
| 02/22/2006 | CN1738624A Method of treatment of myocardial infarction |
| 02/22/2006 | CN1738618A Pharmaceutical compositions and their uses |
| 02/22/2006 | CN1738599A Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
| 02/22/2006 | CN1736452A Medicine for matching with micro-traumatic surgery and its preparing process |
| 02/22/2006 | CN1736262A Composition containing flavonoid, jphosphatidyl inositol and/or inosite |
| 02/22/2006 | CN1243093C Using phenylethyl caffeiate derivative, capsaicin and resin toxin to inhibit NF-KB |
| 02/22/2006 | CN1243021C Interleukin-18 binding proteins, their preparation and use |
| 02/22/2006 | CN1242995C Novel compounds, their use and preparation |
| 02/22/2006 | CN1242992C Cyclic diamine compounds bearing six-membered cyclic groups |
| 02/22/2006 | CN1242814C Protease inhibitor of Ornithotoctonus huwena |
| 02/22/2006 | CN1242813C Combination therapy for osteoporosis |
| 02/22/2006 | CN1242809C Applications of T-BAM (CD40L) technology in preparation of medicine to treat diseases involving smooth muscle cell |
| 02/22/2006 | CN1242787C Beverage capable of turning white hair into black hair |
| 02/22/2006 | CN1242769C Preparation capable of promoting growth and intelligence development for teenagers and children as well as its preparing method |
| 02/22/2006 | CN1242766C Medicine for preventing and treating chronic exhaustion syndrome and preparing method thereof |
| 02/21/2006 | US7002027 Drug delivery enhancing agents with cholic acid and monosaccharide groups for treating cancer by gene therapy; tissue or organs having an epithelial membrane |
| 02/21/2006 | US7002022 treatment of neoplastic diseases that respond to inhibition of the vascular endothelial growth factor receptor tyrosine kinase activity; tumors, retinopathy, macular degeneration |
| 02/21/2006 | US7002019 aryl hydrocarbon; oxidation of 4,5-dihydro-1,3-azoles to fully unsaturated ring; heterocyclic ketones |
| 02/21/2006 | US7002012 Therapeutic treatment of septic shock; chemical condensation reaction by cyclization, amidation, chemical intermediates |
| 02/21/2006 | US7002001 Modified human C3 protein for forming said convertase; use in depleting levels of complement pathway protein; preventing transplant rejection |
| 02/21/2006 | US7002000 Nucleic acid encoding α chain of human IL-11 receptor |
| 02/21/2006 | US7001993 site-directed mutagenesis; high protease-inhibitory activity in absence of heparin |
| 02/21/2006 | US7001980 Monoclonal antibodies directed against the G3BP protein, and uses |
| 02/21/2006 | US7001914 Compounds |
| 02/21/2006 | US7001908 Arylpiperazines having activity at the serotonin 1A receptor |
| 02/21/2006 | US7001907 Peptide-containing α-ketoamide cysteine and serine protease inhibitors |
| 02/21/2006 | US7001902 Cyclization in presence of Lawesson's reagent |
| 02/21/2006 | US7001900 Central nervous system disorders |
| 02/21/2006 | US7001898 Treating conditions involving increased vascular resistance and cardiac insufficiency. |
| 02/21/2006 | US7001769 modulating cellular senescence in vitro by introducing a polynucleotide (gDNA or cDNA) encoding an amphiphysin-1 protein; genetic engineering; genetic disorders, premature aging |
| 02/21/2006 | US7001729 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor |
| 02/21/2006 | US7001718 Prevent complexing of Dna and ligand; viricides; drug mixture with carrier |
| 02/21/2006 | US7001599 Nucleotide sequences coding polypeptide for use in the treatment of inflammatory defects |
| 02/21/2006 | US7001589 comprises liquid core (containing hydrocarbon) and water soluble polymethylacrylamides as skins/envelopes; microencapsulation; kits |
| 02/21/2006 | CA2423825C New perindopril salt and pharmaceutical compounds containing it |
| 02/21/2006 | CA2283399C Pyridazinones as inhibitors of cyclooxygenase-2 |
| 02/21/2006 | CA2250347C Piperazine and piperidine compounds with high affinity for dopamine-d2 and serotonin-5ht1a receptors |
| 02/21/2006 | CA2175372C Novel 9-hydroxy-pyrido[1,2-a]pyrimidin-4-one ether derivatives |
| 02/21/2006 | CA2110443C Guanidinealkyl-1,1-bisphosphonic acid derivatives, process for their preparation and their use |
| 02/16/2006 | WO2006016681A2 Crp lowering agent |
| 02/16/2006 | WO2006016657A1 Drug for treating or preventing hcv infection |
| 02/16/2006 | WO2006016644A1 Antibody and utilization of the same |
| 02/16/2006 | WO2006016637A1 Novel cyclic aminobenzoic acid derivative |
| 02/16/2006 | WO2005062748A3 Bicyclic carbohydrate compounds useful in the treatment of infections caused by herpesviridae |
| 02/16/2006 | WO2003025129A3 Neurotransmission-associated proteins |
| 02/16/2006 | US20060036089 33 human secreted proteins |
| 02/16/2006 | US20060035979 Inhibitors of transcription factor NF-kappaB |
| 02/16/2006 | US20060035957 Preventive or remedy for bedsore |
| 02/16/2006 | US20060035935 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 02/16/2006 | US20060035925 Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 02/16/2006 | US20060035923 Overactive bladder treating drug |
| 02/16/2006 | US20060035916 2,4-Pyrimidinediamine compounds and their uses |
| 02/16/2006 | US20060035878 Novel use of ansamycin antibiotics and method of screening novel angiogenesis inhibitor |
| 02/16/2006 | US20060035875 Remedy for hormone-dependent cancer |
| 02/16/2006 | US20060035870 Carboxylic acid derivatives as IP antagonists |
| 02/16/2006 | US20060035868 2' Hydroxy-3'-bromo-3,4,4',5-tetramethoxy-(Z)-stilbene; antimitotic agent; inhibits the assembly of tubulin into microtubules; anticarcinogenic: solid tumor cancers, neovascularization; tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and A-4 (extract from willow tree) |
| 02/16/2006 | US20060035865 Lipid-rich plaque regressing agents |